ThrowinDice Posted - 48 minutes ago

$BMY interesting...https://www.gbnews.com/health/cancer-breakthrough-new-miracle-treatment-brain-cure

vanguard100 Posted - 4 hours ago

$BMY

stiselini Posted - 7 hours ago

Took profits on $BMY. Feel like technicals are glitchy at the moment.

30AMoney Posted - 7 hours ago

$SPY $BMY dec 20 35p's @ $.05 (A Player sold 85 units). i like this trade~

Vnso123 Posted - 9 hours ago

$PRME any additional share purchasing from $GOOG or $BMY is going to launch this into space. Trading at a big discount right now!

FridayGuy Posted - 22 hours ago

$BMY If this stock beats 2 quarters in a row come 10/31/24 we are going to run hard to the upside

PennyFun Posted - 23 hours ago

$BMY 60$ coming ;holding form 40s 💚✅💚✅

Mike_Check1 Posted - 1 day ago

@onefryshy @ThatStockGuy4 aside for the schizophrenic drug i personally will begin Breyanzi treatment next week. I got insurance but saw how much the insurance company will be paying. My yearly treatment will cost $98,000 most of that going to $BMY. That drug only will be making them hundreds of millions next year.

TalkMarkets Posted - 2 days ago

Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 $JNJ Also $BMY $LLY $ABBV https://talkmarkets.com/content/stocks--equities/johnson--johnson-dividend-stock-analysis-saturday-oct-12?post=465050

ThatStockGuy4 Posted - 3 days ago

Generally #bearish on $BMY. Seems to to have been good value for quite some time but the market doesn't agree & price is what pays.

ClosetIguana Posted - 3 days ago

$BMY

Quantumup Posted - 3 days ago

Piper Sandler raised the PT on $EWTX to $51 was $48 and reiterated at an Overweight rating. Piper Sandler says in its research note: Into 12-month Ph2 CANYON data (December), we think BMD represents a free call option investors aren't recognizing. Specifically, Street expectations are low, but even if sevasemten shows stat sig on CK with directional NSAA trends (base case), this could potentially support a case for accelerated approval filing to drive positive stock movement. Homerun would be stat sig across the board on CK & NSAA, which could strongly enable EWTX to file on these data, thus drive even more share gains (low expectations from investors). Importantly, we think BMD provides upside; even with a CK miss (unlikely in our view), there would be minimal stock impact as investors' valuation primarily rests on HCM (#8). With that, we increased our PT to $51 following positive EDG-7500 HCM data. $cytk $bmy

starbreaker Posted - 3 days ago

$BMY I regret not pulling the trigger on this back in June when it was deeply oversold and it looked like they had washed out all the negatives in Q1 earnings. The Jan2025 45 calls I was looking at are a 6 bagger now. Dropped the ball.

ClosetIguana Posted - 4 days ago

$BMY Don't let them get you off your shares. Everybody and their dog know we're going to have an ER beat at the end of the month.

heweg11 Posted - 4 days ago

$BMY

brief1066 Posted - 4 days ago

$BMY dead to me

m5pmc Posted - 4 days ago

$BMY wtf is with the PA

TheProphetOfProfit Posted - 4 days ago

This has very much been a week of consolidation for $BMY after seeing a breakout of this 12 month inverted head and shoulders on the weekly last week. I still think this will move higher in the coming weeks.

ThrowinDice Posted - 4 days ago

$BMY grinding to $55 by 10/18 with a drop back to $52.50 a the end of the month...$60 before year end if the world doesn't fall apart...

TechnicallySaved Posted - 4 days ago

Hope ya'll didnt let that dip shake you out. Almost pushed the sell button myself but still holding and still predicting $ 55 by 10/18 $BMY https://technicallysaved.com/bullish-on-bmy/

DocPharm Posted - 5 days ago

@thebenchwarmers @EdDwg you can listen to any of it and realize VTP (likely) achieves functional cure of hepatitis B in a great majority of patients with baseline HbSAg <200 IU To get there you need to knockdown that antigen load. How do you knockdown or knockdown expression of a gene? RNAi - Ribonucleic Acid interference / silencing What company has the best TPP thus far in development for a HBV RNAi & already generating data with said RNAi? $ABUS - Imdusiran $BRNS - VTP-300 $BMY could be our suitor. - Nivo seems to be the gem - The roots of the executives, advisory council, and board members of ABUS align -Opdivo loses patent exclusivity in a couple years, AB-101 bridge could reopen that blockbuster potential in other indications

IN0V8 Posted - 5 days ago

$BMY UBS raises target price to $54 from $50

abubnic Posted - 5 days ago

$BMY is up +33% since July. $PFE is up +20% since April. And there are all those dividends in between.

DefenseMania Posted - 5 days ago

$GILD $AZN $PFE $BMY https://finance.yahoo.com/news/arcus-biosciences-present-first-clinical-120000335.html

PFElinepfrenzy1990 Posted - 5 days ago

$BMY - Good.

oldtrader60 Posted - 5 days ago

$BMY They BTFD

onefryshy Posted - 5 days ago

$BMY Great article in the Wall Street journal yesterday about how their schizophrenic drug may be pertinent to Alzheimer's as well.

DocPharm Posted - 5 days ago

@thebenchwarmers @thebenchwarmers leaning towards nivolumab and then talking with $BMY on how to bridge the data from Opdivo to Ab-101. Much of then data can be bridged once they have the SAD/MAD data &amp; that’s for oncology too

Quantumup Posted - 5 days ago

H.C. Wainwright⬆️the PT on $CYTK to $120 was $90 and reiterated a Buy rating. Ahead of next week's CMI focused R&D Day, HCW considers how busy Cytokinetics is and the five major themes to the investment case right now, in its beliefs: $bmy $ewtx

ClosetIguana Posted - 5 days ago

$BMY It's time